Challenges and Opportunities in ADHD:
A Conversation with the Experts

Release Date: September 1, 2011
Date of Last Review: August 14, 2012
Expiration Date: August 31, 2013

Learning Objectives
At the conclusion of this continuing medical education activity, the participant will be able to:

1. Discuss growing evidence that assists clinicians in managing ADHD treatments.
2. Discuss the gaps in evidence concerning diagnosis of complex ADHD.
3. Discuss the implications of comorbidity, genetics, and neuroimaging for practice.
4. Select treatment strategies that balance safety and efficacy during treatment of ADHD.

Target Audience
This educational activity is designed for child and adolescent psychiatrists, pediatricians, family practice physicians, and other healthcare professionals with a special interest in diagnosis and treatment of ADHD in children and adolescents.

Continuing Medical Education Credit
The American Academy of Child and Adolescent Psychiatry is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Academy of Child and Adolescent Psychiatry designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only those hours of credit commensurate with the extent of their participation in the activity.

Method of Participation / How to Earn Credit
The CME activity should take approximately 2.0 hours to complete. The participant should:

1. Complete the pre-test.
2. Review the full content of the activity.
3. Complete the CME post-test and evaluation.
4. A passing score of 70% must be obtained on the post-test in order to receive a CME certificate. You will receive two opportunities to successfully complete the post-test.
5. Participants who complete the pre-test, post-test and evaluation will be issued a CME certificate, which may be printed at their location. No additional certificate will be mailed. This program will be available until August 31, 2013.

Date of Original Release
September 1, 2011

Date of Last Review
August 14, 2012

Expiration Date
August 31, 2013

Commercial Support
This activity is supported through educational grants from Eli Lilly and Company and Shire Pharmaceuticals Inc.

Fee
This continuing medical education activity is provided at no cost to the participant.

Program Faculty

	Laurence L. Greenhill, M.D., Chair Professor of Clinical Psychiatry Director, Research Unit of Pediatric Psychopharmacology Division of Child & Adolescent Psychiatry Columbia University Medical Center New York, NY
	Howard B. Abikoff, Ph.D., Presenter Pevaroff-Cohn Professor Director, Institute for Attention Deficit Hyperactivity and Behavior Disorders, NYU Child Study Center Department of Child and Adolescent Psychiatry NYU Langone Medical Center New York, NY
	Gabrielle A. Carlson, M.D., Presenter Professor of Psychiatry and Pediatrics Director, Child and Adolescent Psychiatry Stony Brook University School of Medicine Stony Brook, NY
	Bennett L. Leventhal, M.D., Director Deputy Director Nathan Kline Institute for Psychiatric Research (NKI) Orangeburg, NY Professor, Deputy Director of Research, and Vice Chair Department of Child and Adolescent Psychiatry New York University Medical Center and NYU Child Study Center New York, NY
	James J. McGough, M.D., Presenter Professor of Clinical Psychiatry Division of Child and Adolescent Psychiatry David Geffen School of Medicine University of California, Los Angeles Los Angeles, CA
	Timothy E. Wilens, M.D., Presenter Pediatric Psychopharmacology Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School Boston, MA

Disclosures
Howard B. Abikoff, Ph.D.
Grant Support: National Institute of Mental Health, National Institute on Drug Abuse
Honorarium: American Academy of Child and Adolescent Psychiatry
Research Support: Hecksher Foundation, Lemberg Foundation
Royalties: School Specialty, Inc., Multi-Health Systems
Travel Support: American Academy of Child and Adolescent Psychiatry

Gabrielle A. Carlson, M.D.
Grant Support: Bristol Myers Squibb, GlaxoSmithKline, National Institute of Mental Health, Pfizer Inc
Honorarium: American Academy of Child and Adolescent Psychiatry
Travel Support: American Academy of Child and Adolescent Psychiatry

Laurence L. Greenhill, M.D.
Honorarium: American Academy of Child and Adolescent Psychiatry
Research Support: Rhodes L.P., Shire Pharmaceuticals Inc.
Travel Support: American Academy of Child and Adolescent Psychiatry

Bennett L. Leventhal, M.D.
Consultant: Eli Lily and Company
Honorarium: American Academy of Child and Adolescent Psychiatry
Leadership Role: Deputy Director, Nathan Kline Institute for Psychiatric Research, Vice Chair, New York University Department of Child and Adolescent Psychiatry
Research Support: Autism Speaks, National Institutes of Health
Travel Support: American Academy of Child and Adolescent Psychiatry

James J. McGough, M.D.
Advisory Board: Eli Lilly and Company, NextWave Pharmaceuticals, Inc., Noven Pharmaceuticals, Sunovion
Honorarium: American Academy of Child and Adolescent Psychiatry
Research Support: Shionogi Pharma, Inc. (formerly Sciele Pharmaceuticals), Sunovion
Travel Support: American Academy of Child and Adolescent Psychiatry

Timothy E. Wilens, M.D.
Consultant: Abbott Laboratories, AstraZeneca LP, Eli Lilly and Company, McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Merck & Co., Inc., NextWave Pharmaceuticals, Inc., Shire Pharmaceuticals Inc.
Grant Support: Abbott Laboratories, Eli Lilly and Company, McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Merck & Co., Inc., National Institutes of Health (National Institute on Drug Abuse), Shire Pharmaceuticals Inc.
Honorarium: American Academy of Child and Adolescent Psychiatry
Past Speaker's Bureau: McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, Shire Pharmaceuticals Inc.
Royalties: Guilford Press
Travel Support: American Academy of Child and Adolescent Psychiatry

Disclosure Declaration
The American Academy of Child and Adolescent Psychiatry requires full disclosure from all presenters and persons in control of the content of the existence of any significant financial interest or other affiliation with a commercial supporter.

It is the policy of the American Academy of Child and Adolescent Psychiatry to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

The author, sponsor, and publisher of this continuing medical education program have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing medical education program. Information regarding medications (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Approval of credit for this continuing medical education program does not imply endorsement by the American Academy of Child and Adolescent Psychiatry of any product or manufacturer identified.

Any medications or treatment methods suggested in this CME activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Contacts
Elizabeth Hughes, Assistant Director of Education and Recertification
202.966.7300, ext. 106
ehughes@aacap.org